Document is current
Any future updates will be listed below
-
Authors
Nevala-Plagemann, Christopher https://orcid.org/0000-0003-4048-2692
Conroy, Thierry
Garrido-Laguna, Ignacio
- License Information
-
More Information
Article History
First Online: 25 October 2024
Competing interests
: C.N.-P. receives institutional research funding from Theriva and has had an advisory role at Seagen. I.G.-L. receives institutional research funding from Revolution Medicine, Quanta Therapeutics, 280 Bio, Bayer, BridgeBio Pharma, Bristol–Myers Squibb, GlaxoSmithKline, Incyte, Jacobio, Lilly, MedImmune, Novartis, Pfizer, Repare Therapeutics, Sumitomo Dainippon Pharma Oncology and Tolero Pharmaceuticals; has had consulting or advisory roles at Jazz, Kanaph, Lilly, OncXerna Therapeutics and SOTIO; and an uncompensated consulting role for Revolution Medicine. T.C. declares no competing interests.
